Clustering of known low and moderate risk alleles rather than a novel recessive high-risk gene in non-BRCA1/2 sib trios affected with breast cancer.
BRCA1 Protein
/ genetics
BRCA2 Protein
/ genetics
Breast Neoplasms
/ genetics
Case-Control Studies
Checkpoint Kinase 2
/ genetics
Female
Genetic Predisposition to Disease
Germ-Line Mutation
Haplotypes
High-Throughput Nucleotide Sequencing
Humans
Multifactorial Inheritance
Pedigree
Polymorphism, Single Nucleotide
Siblings
Exome Sequencing
/ methods
breast cancer
exome
polygenic
recessive
susceptibility
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 11 2020
15 11 2020
Historique:
received:
25
01
2020
revised:
31
03
2020
accepted:
15
04
2020
pubmed:
10
5
2020
medline:
17
4
2021
entrez:
9
5
2020
Statut:
ppublish
Résumé
Breast cancer risk is approximately twice as high in first-degree relatives of female breast cancer cases than in women in the general population. Less than half of this risk can be attributed to the currently known genetic risk factors. Recessive risk alleles represent a relatively underexplored explanation for the remainder of familial risk. To address this, we selected 19 non-BRCA1/2 breast cancer families in which at least three siblings were affected, while no first-degree relatives of the previous or following generation had breast cancer. Germline DNA from one of the siblings was subjected to exome sequencing, while all affected siblings were genotyped using SNP arrays to assess haplotype sharing and to calculate a polygenic risk score (PRS) based on 160 low-risk variants. We found no convincing candidate recessive alleles among exome sequencing variants in genomic regions for which all three siblings shared two haplotypes. However, we found two families in which all affected siblings carried the CHEK2*1100delC. In addition, the average normalized PRS of the "recessive" family probands (0.81) was significantly higher than that in both general population cases (0.35, P = .026) and controls (P = .0004). These findings suggest that the familial aggregation is, at least in part, explained by a polygenic effect of common low-risk variants and rarer intermediate-risk variants, while we did not find evidence of a role for novel recessive risk alleles.
Identifiants
pubmed: 32383162
doi: 10.1002/ijc.33039
pmc: PMC7540545
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
BRCA2 Protein
0
BRCA2 protein, human
0
Checkpoint Kinase 2
EC 2.7.1.11
CHEK2 protein, human
EC 2.7.11.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2708-2716Subventions
Organisme : Cancer Research UK
Pays : United Kingdom
Informations de copyright
© 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Clin Genet. 2015 Oct;88(4):303-12
pubmed: 25470109
Eur J Biochem. 1998 May 15;254(1):63-9
pubmed: 9652395
J Steroid Biochem Mol Biol. 2009 May;115(1-2):20-9
pubmed: 19429457
Eur J Hum Genet. 2010 Aug;18(8):909-14
pubmed: 20407466
DNA Cell Biol. 1996 Jan;15(1):9-16
pubmed: 8561901
Nat Genet. 2002 Jan;30(1):97-101
pubmed: 11731797
N Engl J Med. 2015 Jun 4;372(23):2243-57
pubmed: 26014596
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Nature. 2017 Nov 2;551(7678):92-94
pubmed: 29059683
Int J Cancer. 2019 Oct 1;145(7):1782-1797
pubmed: 31050813
J Clin Oncol. 2016 May 1;34(13):1455-9
pubmed: 26786923
Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2143-51
pubmed: 20826828
Hum Mutat. 2006 Jun;27(6):538-44
pubmed: 16652348
Nature. 2010 Oct 28;467(7319):1061-73
pubmed: 20981092
Nat Genet. 2013 Apr;45(4):353-61, 361e1-2
pubmed: 23535729
J Natl Cancer Inst. 2015 Apr 08;107(5):
pubmed: 25855707
Nat Genet. 2014 Aug;46(8):818-25
pubmed: 24974849
Am J Hum Genet. 2002 Sep;71(3):595-606
pubmed: 12181777
Int J Cancer. 1997 May 29;71(5):800-9
pubmed: 9180149
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Am J Hum Genet. 2004 Jun;74(6):1175-82
pubmed: 15122511
JAMA. 2008 Mar 26;299(12):1437-45
pubmed: 18364486
Nat Genet. 2015 Jun;47(6):643-6
pubmed: 25915596
Am J Hum Genet. 2019 Jan 3;104(1):21-34
pubmed: 30554720
Genet Med. 2016 Aug;18(8):823-32
pubmed: 26681312
Genes Chromosomes Cancer. 2008 Nov;47(11):947-56
pubmed: 18663745
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
PLoS Genet. 2009 Jun;5(6):e1000529
pubmed: 19543373
Nature. 2005 Oct 27;437(7063):1299-320
pubmed: 16255080
Genome Res. 2007 Dec;17(12):1723-30
pubmed: 18055845
Hum Mol Genet. 2015 Sep 15;24(18):5345-55
pubmed: 26130695
Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15172-7
pubmed: 25288723
Genet Med. 2017 May;19(5):599-603
pubmed: 27711073
Am J Hum Genet. 2001 Feb;68(2):420-31
pubmed: 11133358
Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1045-52
pubmed: 14578141
Oncogene. 2017 Jul 20;36(29):4161-4170
pubmed: 28319063
Cancer. 2004 Apr 1;100(7):1345-51
pubmed: 15042666
PLoS Genet. 2015 May 06;11(5):e1005228
pubmed: 25945795
Int J Cancer. 2020 Nov 15;147(10):2708-2716
pubmed: 32383162
Genet Epidemiol. 2001 Jul;21(1):1-18
pubmed: 11443730
Biochem J. 2010 Jul 1;429(1):157-69
pubmed: 20423326
Lancet. 2001 Oct 27;358(9291):1389-99
pubmed: 11705483
Nat Genet. 2014 Mar;46(3):310-5
pubmed: 24487276
J Clin Oncol. 2012 Dec 10;30(35):4330-6
pubmed: 23109704
Breast Cancer Res Treat. 2016 Aug;158(3):463-9
pubmed: 27438779
Br J Cancer. 2002 Jan 7;86(1):76-83
pubmed: 11857015
J Med Genet. 2019 Sep;56(9):581-589
pubmed: 31186341
Mol Aspects Med. 2013 Apr-Jun;34(2-3):494-515
pubmed: 23506885
Cancer. 2015 Jan 1;121(1):25-33
pubmed: 25186627